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Abstract
Background: Hand osteoarthritis (OA) is a common condition, causing pain, stiffness and reduced quality of life.
Incidence is higher amongst women, particularly around the age of the menopause. Whilst the relationship
between sex hormones and OA has been studied in vitro, in epidemiological studies and in clinical trials of
hormone replacement therapy (HRT), this study is the first to investigate the effect of estrogen-containing therapy
on hand pain in post-menopausal women with symptomatic hand OA in a randomised study design.
Methods: This is a feasibility study of a double-blinded placebo-controlled intervention with 1:1 randomisation to
either a combination of conjugated estrogens 0.45 mg and bazedoxifene acetate 20 mg (Duavive) or placebo. The
target population is post-menopausal women with symptomatic hand OA, aiming to recruit 60–90 study
participants. The primary objective is to assess the feasibility of a future fully powered randomised controlled trial
(RCT). Participants will take the study medication for 24 weeks and be followed up for 28 weeks after
randomisation. The primary outcomes used to determine feasibility are eligible participant identification rates and
routes; recruitment, randomisation and retention rates of eligible participants; study medication compliance; and
the likelihood of unintentional unblinding. Secondary outcomes include measures of hand pain, function,
appearance and menopausal symptoms. An end of study questionnaire and focus groups will help to refine the
final protocol for a full study.
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Discussion: Identifying new treatments for symptomatic hand OA is a recognised research priority. The study will
help us to understand whether there are sufficient interested and eligible individuals in this target population who
would consider HRT for their hand symptoms. It will provide proof-of-concept RCT data on the effects of HRT on
hand pain and other clinically relevant outcomes in this population. The study will gain valuable information on the
feasibility of a full RCT and how best to run this. The findings will be published in a peer-reviewed journal and
presented at a relevant conference.
Trial registration: ISRCTN12196200 registered on 15 January 2019.
Keywords: Hand osteoarthritis, Estrogen, Hormone replacement therapy, Clinical trial, Feasibility
Background
Hand osteoarthritis (OA) affects approximately 2 million
people in the UK. The most common symptoms are
hand pain, stiffness and functional difficulties. This can
affect independence and the ability to work with associ-
ated negative health and social consequences [1, 2]. Typ-
ically characterised by an early, painful inflammatory
phase and bony remodelling, the condition may involve
the interphalangeal joints of the thumb and the fingers
(proximal and distal interphalangeal joints) and the base
of the thumb [3]. Patients may have only interphalangeal
joint involvement, only base of thumb involvement or
both.
Recommendations for the management of hand OA
include general advice on joint protection, hand exer-
cises, splinting, analgesia (such as topical anti-
inflammatory gel) and sometimes intra-articular steroid
injections (although their routine use is somewhat con-
troversial) [4–6]. Whilst these treatments are often help-
ful, their effectiveness is frequently modest and they are
not suitable for the entire population with hand OA [7–
9]. Surgery remains an option in severe cases of hand
OA [8]. Around 90% of those seeking specialist care for
symptomatic hand OA are female [10]. Six hundred
twenty thousand women aged 45–64 sought treatment
for hand OA within UK primary care over a 7-year
period [11]. The incidence of hand OA is higher in
women than men at all ages; however the greatest rela-
tive risk compared with men is at the age of 50–55
years, which is around the age of menopause, a time of
hormonal change and progressive estrogen deficiency
[12–15].
There is evidence from a number of other sources that
estrogens may be important in OA. Connective tissues
including articular cartilage and bone have estrogen re-
ceptors and make aromatase, which synthesises estrogen
in local tissues. Anti-estrogens such as aromatase inhibi-
tors used to treat breast cancer can precipitate musculo-
skeletal pain or flares of symptomatic OA [16, 17].
Times of low estrogen can be associated with pain vul-
nerability in women, potentially exacerbating pain in the
context of disease [18, 19].
Women may take hormonal replacement therapy
(HRT) to control menopausal symptoms such as hot
flushes, sweats and gynaecological symptoms associated
with estrogen deficiency. For women with an intact
uterus, HRT formulations must include progestogens or
selective estrogen receptor modulators (SERMs) in
addition to estrogens; this is to reduce the risk of endo-
metrial hyperplasia and cancer [20]. SERMs are a group
of agents which bind to estrogen receptors [21]. The
benefits of HRT need to be considered in the context of
individual risk factors, particularly female cancers and
thromboembolic disease [22, 23]. First time prescription
of HRT to women who are more than 10 years post-
menopause or over 65 years of age is inadvisable and
may have accounted for much of the morbidity in earlier
studies, as reflected in the current prescribing guidelines
[24–27].
To date, there have been no randomised controlled tri-
als (RCTs) or proof-of-concept studies testing HRT in
individuals with symptomatic hand OA. Observational
HRT studies using varying combinations of hormones
give conflicting results, perhaps because of confounding
factors in those with musculoskeletal symptoms seeking
or commencing HRT [13]. In post hoc analysis from
large HRT clinical trials, there was evidence for a benefi-
cial effect on musculoskeletal pain in those receiving
conjugated equine estrogens (CEE), some of whom
probably had OA [28]. Similarly, when studying hip and
knee OA in HRT clinical trial data, modest protection
from hip and also knee replacement were seen in those
receiving CEE alone [29, 30]. Effects of HRT on hand
OA were not specifically examined in these trials. How-
ever beneficial effects of HRT in hand OA are suggested
by some epidemiological study data [31, 32].
SERMs could also have beneficial effects in OA [33].
Unlike ‘standard’ HRT, which tends to give conflicting
results, consistent improvements have been reported
with SERMs in animal models of OA [33–35]. In a single
reported clinical trial, raloxifene improved back and
knee pain, some of which was attributable to OA [36].
Newer SERMs such as bazedoxifene have a better safety
profile than early-generation SERMs such as raloxifene.
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However, unwanted effects such as worsening post-
menopausal flushing still limit acceptability of SERMs as
lone agents.
Aiming to mitigate the issues of either compound used
alone, Duavive was developed by Pfizer as a first-in-class
combination of CEE and bazedoxifene. Duavive was ap-
proved in the US and the EU in 2014 for symptoms of
estrogen deficiency. It reduced hot flushes and improved
menopausal quality of life with a good safety profile [37,
38]. This combination showed no significant breast or
endometrial risk compared with placebo after 2 years in
several large phase III trials [39].
We aim to test the hypothesis that Duavive can im-
prove average hand pain in post-menopausal women
with symptomatic hand OA. We will not test the indi-
vidual components (estrogen and bazedoxifene) in view
of the safety and tolerability considerations outlined
above. The combination agent (or matched placebo)
would be used here in all women, irrespective of uterine
status, given the mechanistic hypothesis that both com-
ponents (estrogen and bazedoxifene) may have effects
on OA hand pain and disease. It is also possible that this
estrogen-bazedoxifene combination may be more ac-
ceptable and more effective than either treatment alone.
Given a lack of precedent for RCTs in this area and un-
certainties regarding recruitment, retention and proof-of
concept data (including estimated effect size), a feasibil-
ity study was designed. The Hand Osteoarthritis: investi-
gating Pain Effects of estrogen-containing therapy
(HOPE-e) feasibility RCT aims to address these uncer-
tainties and to inform the design of a future adequately
powered multicentre randomised trial.
Methods
Study design
HOPE-e is a parallel group, double-blind randomised
placebo-controlled interventional study to test the feasi-
bility of using a licensed form of HRT (Duavive) for an
alternative indication. The study examines the feasibility
of a full trial, including recruitment; acceptability of ran-
domisation; acceptability and tolerability of the medica-
tion and tests; the selection and acceptability of the
proposed outcomes. Patient and public involvement
(PPI) actively informed the rationale, design and devel-
opment of protocol and patient facing materials of this
study. Similarly, an end of study questionnaire and focus
group delivered after week 28 will give study participants
the opportunity to contribute to the refinement of the
procedures for a future definitive trial.
Primary objective
To assess the feasibility of a future fully powered RCT of
Duavive in post-menopausal women with hand OA
based on the following outcomes:
 Eligible participant identification rates and routes
 Recruitment, randomisation and retention rates
 Compliance (participant reported)
 Likelihood of unblinding
Secondary objectives
To refine outcomes for the full study and generate
proof-of concept data (including estimated effect size)
on whether estrogen-containing therapy improves hand
pain and other secondary outcomes in post-menopausal
women with hand OA. Secondary outcomes will assess
hand pain and function, menopause symptoms and joint
appearance. Average hand pain will be recorded daily
over the 14 days preceding each study visit, as well as
the recalled average hand pain for the past 14 days at
the study visit. Daily pain rating will either be by smart
phone or by paper diary, depending on participant pref-
erence (see “Data collection methods” section). All out-
come measures to address the primary and secondary
objectives are listed in Table 1.
The protocol follows the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
guidelines [50]. The SPIRIT checklist is provided as Sup-
plementary Table 1 in the Additional files.
Study setting
This feasibility study will be undertaken at a small num-
ber of sites, including a range of primary and secondary
care National Health Service (NHS) sites in the UK. Par-
ticipants will also be recruited directly from the commu-
nity, through participant identification centres and via a
number of advertising methods. A list of the study sites
can be provided on request from the HOPE-e study
office.
Eligibility criteria
In order to be eligible for the study, patients must com-
ply with all of the following:
 Able to give written informed consent
 Female aged 40–65 years old
 In those with an intact uterus: at least 12 months of
spontaneous amenorrhea (without any menstrual
bleeding in last 12 months) and last menstrual
period not more than 10 years ago
 In those who have undergone hysterectomy or are/
were using an intrauterine contraceptive device with
progesterone local therapy (such as MirenaTM):
follicle stimulating hormone (FSH) ≥ 30mIU/ml) on
screening blood test and a history of menopausal
symptoms in the last 1 to 10 years, in keeping with
appropriate timing of menopausal status
 Hand pain, aching or stiffness on most days in the
last 3 months and fulfils American College of
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Rheumatology clinical diagnostic criteria for hand
OA (3 or more of the following) [51]:
○ Hard tissue enlargement of two or more of the
following joints: 2nd or 3rd distal interphalangeal
joints (DIPJ), 2nd or 3rd proximal interphalangeal
joints, first carpometacarpal joints
○ Hard tissue enlargement of two or more of the
DIPJs
○ Fewer than three swollen metacarpophalangeal
joints
○ Deformity of at least one of the joints listed in
the first point
 Minimum of two painful hand joints of any type
(interphalangeal joints (IPJ) or base of thumbs)
 Hand pain that has not responded adequately to
National Institute for Health and Clinical Excellence
(NICE) core guidance for the management of OA
[27], including the use of paracetamol or non-
steroidal anti-inflammatory topical gel, except where
there is contraindication or intolerance
 Average hand pain is reported as typically more
than 4 out of 10 in severity, or average hand pain in
the last 7 days of 4/10 or more on a visual analogue
scale
 Able and willing to comply with all study
requirements
Participants may not enter the study if any of the fol-
lowing apply:
 Other cause of hand pain, including inflammatory
arthritis, connective tissue disorder, chronic pain, or
alternative clinical diagnosis such as tenosynovitis or
carpal tunnel syndrome
 Pregnancy or breast feeding, or risk of this during
study
 Use of one or more prohibited treatments within
specified timeframe, or not willing to avoid
treatment for the duration of the study (see
additional details in Supplementary Table 2)
 Presence of one or more medical contraindications
to the use of systemic hormonal replacement
therapy (see additional details in Supplementary
Table 2)
 Any other significant or uncontrolled disease or
disorder which may either put the participants at
risk because of taking part in the study, or may
influence the result of the study, or the participants’
ability to participate
 Participants involved in another research trial
involving an investigational product in the past 8
weeks
Blood and urine testing
Blood samples will be taken at screening as part of the
eligibility process and at weeks 4, 12, and 24 for moni-
toring the safety of therapy. A mid-stream urine sample
will be tested by dipstick for blood, protein and glucose
at screening. The urine sample will be used to perform
beta human chorionic gonadotropin (β-HCG) testing by
test stick to exclude pregnancy, at the investigator’s dis-
cretion. For safety reasons, at all other visits, a urine dip-
stick for blood, protein, and glucose or urinary β-HCG
testing can be performed at the discretion of the
investigator.
Pregnancy and contraception
Duavive is only licensed for use in postmenopausal
women and is contraindicated in women who are, or
may become, pregnant. If pregnancy occurs during treat-
ment, Duavive should be withdrawn immediately. Indi-
viduals entering the study must be at least 1 year after
natural cessation of periods. A urinary pregnancy test
will be conducted at the screening visit and subsequent
visits at the investigator’s discretion, for example in
those who are within 2 years of final menstrual period,
Table 1 Outcome measures
Primary objectives outcome
measures
Secondary objectives outcome measures
Pain and function outcomes Menopause symptoms Joint appearance
• Rates of eligible participant
identification (screening period)
• Rates of recruitment/
randomisation from different
sources (screening period)
• Retention rates (throughout
study)
• Study medication compliance
a
• Bang’s Blinding Index
(likelihood of unblinding) [40] a
• Average hand pain (rated over 14
days preceding the study visit)c a
• Pain manikin–capturing pain in
other joints in the 4 weeks
preceding the study visita
• Functional Index for Hand
OsteoArthritis (FIHOA)
questionnaire [41, 42]b
• Grip strength, by Jamar
dynamometer [43]b
• EQ-5D-5L questionnaire [44, 45]b
• Menopause-specific Quality of Life (MEN-
QOL) questionnaire (Intervention 1-month
recall version) [38, 46, 47]b
• Greene Climacteric Scale [48]b




der and swollen joint
counts a
• Photographic recording of
swollen hand joints a
aSee Fig. 1 for collection time points
bSee “Questionnaires” in Table 2 for collection time points
cProposed primary outcome for full trial
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and/or under the age of 45. Where there is clinical con-
cern, those individuals will be advised to use two reliable
methods of barrier contraception.
Interventions
In the intervention group, conjugated estrogens 0.45
mg-bazedoxifene acetate 20mg (Duavive, Pfizer) will be
administered orally as a tablet once daily for 24 weeks.
There is no possibility for dose modification during the
study. A matched placebo was manufactured and pack-
aged by MODEPHARMA Ltd., UK. The placebo and the
study medication tablets are in blister packs and will be
placed in opaque plain box packaging at the time of dis-
pensing. Members of the research team and staff con-
ducting participant visits will not handle the study
medication, and participants will be asked to return un-
used medication to the local pharmacy for safe disposal.
Study participants, care providers, study team (except
the statistician and one other member of the study team)
and outcome assessors will be blinded to intervention.
Participant timeline
The timeline for participants is illustrated in Fig. 1.
Recruitment
Potentially eligible participants will be identified and
approached via multiple routes in order to maximise re-
cruitment. These include discussion at routine clinic ap-
pointments (primary care and different specialties in
secondary care including rheumatology, orthopaedics,
hand surgery and therapies); contacting individuals who
have registered an interest in OA research; publicity
leading to self-referral, both online (websites, Twitter
and other social media, Short Message Service (SMS))
and offline (posters and flyers displayed in secondary
care research sites, general practice surgeries and com-
munity spaces such as physiotherapy clinics and phar-
macies, community magazine advertising). Following
provision of a Participant Information Leaflet (PIL) to
those expressing interest, key eligibility criteria will be
assessed in those verbally consenting to an initial tele-
phone pre-screen, following which individuals will be in-
vited to attend a screening visit in person at the nearest
recruitment site.
Consent
A medically qualified and GCP trained clinician will ob-
tain informed consent from the patient at the screening
visit at least 24 h after receiving the PIL, following pa-
tient verification of understanding of all aspects of the
study and having answered all questions and document-
ing this by completion of the study informed consent
form.
Screening assessment
Following consent, full eligibility, including that assessed
by blood test results, will be reviewed as part of the
screening assessment and prior to randomisation (see
Fig. 1). An X-ray of both hands is also offered at the end
of screening visit to all those who appear eligible and
who have not undergone a hand X-ray in the last 3
years. Although the presence of radiographic hand OA
is not required for inclusion in the study, its presence or
absence will be reported for participants entering the
study. Should an individual fail to meet eligibility criteria
at screening assessment based on a reversible criterion
(e.g. initiation of oral analgesia within 4 weeks of screen-
ing visit), re-screening may be carried out if the partici-
pant agrees. If a participant fails to meet the inclusion
and exclusion criteria on review of results from the
screening visit, they will be withdrawn and not proceed
with the study. They will be contacted with an explan-
ation and advice as appropriate.
Randomisation
Consenting, eligible participants will be randomised 1:1
to either Duavive or placebo at the baseline visit. Ran-
domisation to the interventions will be carried out via a
secure (encrypted) web-based randomisation service, the
Oxford Clinical Trials Research Unit (OCTRU) Registra-
tion, Randomisation and Management of Product
(RRAMP). Randomisation will be performed using a
minimisation algorithm including a random element to
ensure balanced allocation of participants across the two
treatment groups, stratified by centre and the profile of
painful joints (IPJ hand OA only; IPJ plus base of thumb
OA; or base of thumb OA only) [52]. To prevent pre-
dictability, the minimisation algorithm will be seeded,
randomising the first few participants using simple ran-
domisation. Specific details will be stored within a ran-
domisation and blinding plan, stored securely in the
confidential statistical trial master file.
Data collection methods
Study outcome data will be collected during five face-to-
face study visits and one remote visit. Details of visit
timings and outcomes are presented in Fig. 1 and
Table 2; these are the following:
 Screening (eligibility)
 Baseline (randomisation, first prescription of study
medication)
 4 weeks (safety, adherence)
 12 weeks (safety, adherence, second prescription of
study medication)
 24 weeks (primary outcome, advice on weaning
study medication over subsequent 4 weeks)
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 28 weeks phone call (safety, review of weaning of
study medication)
We anticipate that any effects of the intervention on
symptoms would be evident by between 4 and 24 weeks
after initiation; therefore, the main outcomes will be col-
lected at baseline, week 12 and week 24. Face-to-face
visits will be necessary to assess for Adverse Events
(AEs), provide new prescriptions and perform safety
blood tests in addition to collection of other data (Fig. 1
and Table 2).
There will be a 28-week phone call to review progress
following weaning of study medication after 24 weeks
(best practice is to avoid abrupt cessation of HRT and
this allows for this) and collect/assess any AEs. Some
consenting participants will be randomly selected to at-
tend one of two optional focus groups after week 28.
Outcome data will be collected via Paper Case Report
Forms completed by the investigator and participant. Re-
mote daily rating of hand pain in the 14 days prior to a
study visit will be captured on paper diaries or via the
use of a single response online questionnaire
Fig. 1 Study flow chart
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(Limesurvey) sent to the participant’s smart phone via
SMS, depending on the participant’s preference.
Data management
All study data will be entered into a secure password-
protected database (OpenClinica®), except for the elec-
tronic remote daily pain rating which is automatically
stored in the study database. All hand photographs,
audio recordings and transcripts of focus groups will be
kept in a linked anonymised format and stored securely.
Audio recordings will be deleted at the end of the study.
A Data Management Plan which includes references to
confidentiality, access and security arrangements has
been produced for the study and is available on request
from the HOPE-e study office.
Concomitant medications
Concomitant medication will be recorded at each visit.
The participants will be immediately discontinued from
the study medication if they commence any other sys-
temic hormonal therapy (such as another form of sys-
temic HRT or the oral contraceptive pill), any form of
anti-estrogen medication or initiation of a liver-enzyme
inducing agent. The medications or interventions
Table 2 Timing of visits and data collection (SPIRIT)
Visits/time points
1 2 3 4 5 6
Procedures Screening Baseline Follow-up
Maximum 42 days Week 0 Week 4 Week 12 Week 24 Week 28
Informed consent x
Inclusion/exclusion x x x x x
Demographics x
Medical history x
Concomitant medication x x x x x
Hand pain 0–10 NRS x x x x x
Pain manikin x x x
Physical examination x x x x
Vital signs x x x x
Blood screening x
Urine dipstick x Xa Xa Xa Xa
Urine pregnancy test Xa Xa Xa Xa Xa
Bilateral hand X-ray (if applicable) x
Hand pain rating (remote) Training x x x x
Randomisation x
Prescription/dispensing x x
Reported study medication compliance x x x
Advice on barrier contraception Xa Xa Xa Xa
Joint count x x x
Questionnaires x x x
Photographs of swollen hand joints x x x
Grip strength x x x
Safety blood monitoring c x x x
Safety/adverse events x x x x
Advice on weaning off study medication x
Bang’s Blinding Index x
End of treatment questionnaire x
Focus groupb (optional)
aAt discretion of investigator
bAfter last participant has completed visit 6
cIncludes creatinine, urea and electrolytes, liver function, full blood count and C-reactive protein
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described in Table 3 will be discouraged during the
study; their use will be documented, but the participant
will be allowed to remain in the study.
Compliance with the study medication
Clinically significant non-compliance will be defined as
more than 14 days of missed medication in any calendar
month, following which the participant will be with-
drawn from study medication but invited to continue
study follow-up.
Breakthrough pain relief medication
Participants may experience flares of hand pain during
the study. During this time, they should take their usual
analgesic medications as required. If possible, no new
medications should be commenced for pain in the hand
or elsewhere. Where paracetamol is not usually taken
already, participants will be instructed that they can use
paracetamol up to 1 g four times daily for the relief of
breakthrough pain if they wish, preferably avoiding tak-
ing any in the 24 h prior to a study visit. Any use of such
breakthrough pain relief will be documented at each
visit, and the participant asked to record this in their
study paper diary.
Statistical analysis
As this is a feasibility study not aiming to assess treat-
ment effects but to test rates and feasibility of random-
isation, a formal power calculation was not conducted.
Instead we estimated 60–90 participants as the number
required for the feasibility study in order to be able to
accurately calculate a sample size that could detect a
moderate standardised effect size of 0.3 to 0.5 in the fu-
ture definitive trial [53]. Outcome data from this number
of participants will be used to estimate standard devia-
tions and confidence intervals (CIs) of the treatment es-
timates which will be used to inform a sample size
calculation for a definitive trial.
The primary analysis will evaluate the feasibility of this
study design based on the outcome measures for the pri-
mary research objectives described in Table 1: rates of
eligible participants; rates of recruitment/randomisation;
retention rates; and study medication compliance. These
outcomes will be reported on an intention-to-treat (ITT)
basis for each treatment group, with sensitivity analyses
conducted on a per protocol (PP) basis. The PP popula-
tion will exclude any participants with protocol devia-
tions pre-specified in the analysis plan, such as reported
non-compliance with the medication or reported con-
comitant medications use (as per Table 3). We will iden-
tify those who completed the study PP prior to
unblinding of any analyses. Mean and standard devi-
ation, or median and interquartile range, will be pre-
sented for continuous outcomes, depending on
distribution, and numbers with percentages for binary
and categorical data, for all planned primary and also for
secondary outcome measures. Demographic and clinical
characteristics for the two groups at baseline will be pre-
sented descriptively. Results will be reported descrip-
tively as per Fig. 2 and in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
extension to randomised pilot and feasibility trials [54].
The secondary objective outcome measure, average
hand pain is the planned primary outcome for the future
definitive trial. This outcome is scored as 0–10 on a Nu-
merical Rating Scale and collected from participant daily
pain ratings for the 14 days prior to the baseline (week
0) and the week 24 study visit. The participant prefer-
ence for hand pain data collection (online questionnaire
or paper diary) will be compared and reported. Average
hand pain will be reported as means and 95% CI based
on a multivariate linear regression model with adjust-
ment for the minimisation factors: study site (3 levels),
and pattern of involvement of painful joints (IPJ hand
OA only, IPJ plus base of thumb OA, or base of thumb
OA only). This will be compared descriptively with the
recalled average hand pain over the last 14 days at each
visit, in terms of completion rates and differences be-
tween these measures. The change in average hand pain
from baseline to 24 weeks and the difference in the
means together and the corresponding 95% CI will also
be reported for each treatment group and overall. No
formal statistical testing will be undertaken, as the study
is not powered for this purpose. Additional analyses will
include blood monitoring and safety data; pre-screen
and screen-out rates; willingness to be randomised if eli-
gible; and other measures of acceptability, including re-
tention rates both overall and by recruitment site;
response in those with IPJ hand OA only, IPJ and base
of thumb OA, and base of thumb OA only; and those
with or without evidence of radiographic hand OA. Fur-
ther analysis outside of this primary analysis plan may
be necessary to fully understand the feasibility of this
study and to inform the future definitive trial. If this oc-
curs, such analysis will be described in full in any results
Table 3 Concomitant medications
• Intra-articular steroid, particularly when into the hands or within 3
months of the week 24 visit
• Oral steroid, particularly when for longer than 5 days consecutively or
within 6 weeks of the week 24 visit
• Intramuscular steroid at any point during the study
• Use of intra-articular hyaluronan to a hand joint at any point during
the study
• New prescription of non-steroidal anti-inflammatory drugs or other
analgesic, particularly when within 4 weeks of the week 24 visit
• Initiation of treatment such as glucosamine or chondroitin at any
point
• Initiation of hand exercises or other relevant non-pharmacological
therapy at any point
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publication arising from this feasibility study. Reasons
for participant unblinding; missing data; withdrawals or
loss to follow-up will be carefully considered and re-
ported by treatment group and patterns of ‘missingness’
will be explored.
Data will be analysed using an appropriate validated
statistical software such as Stata, StataCorp LP, USA
[55]. No comparative interim analyses will be performed.
A trial statistician will contribute to the statistical as-
pects of the study.
Data monitoring
A monitoring plan has been developed and will be
followed throughout the study. A Trial Steering Com-
mittee (TSC) will oversee the overall conduct of the
study and make recommendations on the feasibility of a
full trial following completion. The TSC will comprise of
invited expert members, including at least one medically
qualified person, and patient representatives. A separate
medically qualified Safety Oversight Clinician (SOC)
(with appropriate clinical experience and independent to
the study) will be appointed to safeguard the interest of
the study participants. The SOC can advise the chair of
the TSC at any time, if in their view, the study should be
stopped due to concerns over participant safety.
Stop-go criteria for progression to a future definitive
trial were predefined at the outset of the study. These
were (i) recruitment of sufficient participants in a de-
fined period (pre-specified as ≥ 30 participants across all
sites in 18 months, or, proportionate to this e.g. ≥ 22
Fig. 2 CONSORT pilot and feasibility trials flow diagram schematic
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participants in 12 months); (ii) a drop-out rate of ≤ 30%
of randomised individuals; and (iii) acceptability to the
majority of participants, including acceptable rates of
AEs. The TSC will make recommendations on the feasi-
bility of a future definitive trial based in part, on all three
of these pre-defined criteria being met.
Withdrawals
Participants have the right to withdraw from the study
at any time and without giving reason. Participants ask-
ing to stop treatment or unable to tolerate the treatment
will be withdrawn from the treatment. In the event of in-
eligibility (either arising during the study or retrospect-
ively having been overlooked at screening) the
participant will be withdrawn. The investigator may dis-
continue a participant from the study medication at any
time if the investigator considers it necessary for any
reason (e.g. unblinding; pregnancy; surgical procedures
to the hand; AEs necessitating withdrawal of HRT; new
diagnosis of cancer). Withdrawn participants will be
given advice on weaning treatment if relevant, depending
on the safety considerations. Those withdrawn from the
study will be invited to an optional end of study visit at
the time of their withdrawal.
Safety
All AEs will be collected at all visits as part of assessing
the acceptability of the medication. These data will be
summarised and reviewed by the SOC and the TSC.
However, as this is a feasibility study with a licensed
medication and an established safety profile, only rare
events (≥ 1/10,000 to < 1/1000, i.e. venous thrombo-
embolic events including pulmonary embolism, retinal
vein thrombosis, deep vein thrombosis and thrombo-
phlebitis) and any other serious event deemed to be re-
lated and unexpected will be reported to the sponsor.
Worsening of the underlying disease as a direct result
of the study medication will be reported as a Serious Ad-
verse Reaction (SAR).
All serious adverse events (SAEs) will be reported to
the trials unit within 24 h of the study team becoming
aware. The relationship of each AE to the study medica-
tion will be determined by a medically qualified individ-
ual. These SAEs will also be reported to the Research
Ethics Committee that gave a favourable opinion of the
study if the chief investigator believes the event was ‘re-
lated’ (i.e. resulted from administration of any of the re-
search procedures) and ‘unexpected’ in relation to those
procedures.
In the event of a SAR or any suspicion of a SAR, the
study medication will be stopped immediately. Stopping
medication will also be considered for any AEs as part of
the review process.
The following instances will also be reported as an AE
and will need further investigation if they occur:
1. Those who experience postmenopausal bleeding
and unblinding are carried out and they are shown
to be on placebo.
2. Those who experience persistent or severe bleeding,
ongoing bleeding beyond 12 weeks, or new bleeding
after 12 weeks of taking Duavive (may represent a
SAE), depending on the underlying cause and the
medical response to this.
When a participant has reported vaginal spotting or
bleeding, they will be provided with a ‘breakthrough
bleeding diary’ to record information on the nature and
frequency of bleeding. Unblinding or withdrawal of
study medication may be considered, and the advice of
the study gynaecologist will be sought, particularly if fur-
ther investigation is required. These events may repre-
sent a SAE, depending on the underlying cause. A trial
specific instruction document has been designed to out-
line the review process in detail and is provided as Sup-
plementary Figure 1 in Additional files.
Unblinding
Emergency and non-emergency unblinding will be avail-
able via the RRAMP system 24 h a day.
Accidental unblinding (for example due to break-
through bleeding) of the participant or the investigator
may occur and will be documented in an unblinding log,
and its likelihood will be assessed at the end of the
study. Accidental unblinding will not affect the majority
of primary feasibility outcomes and participants would
therefore be encouraged to continue their medication
and complete the study. If a participant’s allocation is
unblinded for safety reasons during the study, the par-
ticipant will be withdrawn from medication at that point
but invited to attend follow-up study visits and complete
the study.
Auditing
Direct access will be granted to authorised representa-
tives from the sponsor, host institution and the regula-
tory authorities to permit study-related monitoring,
audits and inspections.
Ancillary and post-trial care
There is no provision for continuation of the medication
beyond the end of the study. If participants are eligible
for HRT due to symptoms which are within standard in-
dications for HRT use, the participant will be advised to
discuss this with their GP.
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Dissemination policy
Reporting of the HOPE-e study will be in line with the
CONSORT extension for randomised pilot and feasibil-
ity trials guidelines [54] and will be agreed at TSC meet-
ings. The results of the study will be published and
disseminated via oral reports at international meetings
and on University of Oxford websites. Study results will
be disseminated to study participants via letters follow-
ing end of study and analysis.
Protocol amendments
Favourable opinion of two substantial amendments was
obtained on 9 August 2019 and 18 December 2019. A
history of the protocol amendments is presented in Sup-
plementary Table 3.
Confidentiality
The study staff will ensure that the participants’ confi-
dentiality is maintained. The study will comply with the
General Data Protection Regulation and Data Protection
Act, which requires data to be anonymised as soon as it
is practical to do so. Any communication containing
participant identifiable data from sites will be by NHS.
net email or secure encrypted fax. The participants will
be identified only by a participant code on all study doc-
uments and study database. All documents will be stored
securely and only accessible to authorised personnel.
Declaration of interests
Duavive was purchased through the Oxford University
Hospitals NHS Foundation Trust Pharmacy Purchasing
and Distribution Unit and distributed to sites. The selec-
tion of study medication was on academic grounds. Pfi-
zer had no part in the conception, funding or provision
of study medication for this study.
Discussion
There is an ongoing search to identify pharmacological
therapies which improve pain or target underlying dis-
ease processes in OA, slowing its progression. The pre-
ponderance of symptomatic OA in post-menopausal
women, with a particularly close association between the
age of menopause (~ 50 years) and the incidence of
hand OA, makes targeting estrogen-related pathways an
attractive proposition in this disease.
Not all women can take HRT safely. Despite a large
amount of supporting safety data since the Women’s
Health Initiative in appropriate age groups nearer to
menopause, there remains distrust amongst some of the
public, the media and parts of the medical profession
about the use of HRT. Considering attitudes to medica-
tions in the acceptability and feasibility of this interven-
tion is therefore critical, particularly in terms of the
perceived risk and benefit of taking a medication in this
target population.
The choice of agent in the study was important. Here,
we have chosen a combined oral HRT: an estrogen and
a SERM. By arguing mechanistically for both compo-
nents, we have justified administration to all partici-
pants, irrespective of uterine status (usually those with
hysterectomy would just take unopposed estrogen as
HRT). We have selected an agent based on the preclin-
ical/clinical data supporting likelihood of effect (of both
components), the reported lower incidence of break-
through bleeding with this agent and because partici-
pants in our discussion group were attracted by this
newer agent, especially as both components may have a
positive effect. If an efficacy signal is seen (although not
powered for this), this study would not demonstrate
which element of the agent was mediating this. Subse-
quent mechanistic studies would be needed to deconvo-
lute any effect.
Much of our evidence implicating the menopause in
the onset of hand OA and for estrogen as a relevant tar-
get to date is circumstantial: from epidemiological stud-
ies, observational studies and convenience data from
large HRT trials. There is further insight from a recently
published report (since the development of our protocol)
from electronic healthcare data in UK Community Prac-
tice Research Datalink [15]. This analysis emphasises the
close temporal link to menopause (the highest rates of
hand OA were seen in the year after menopause), but
not all women have a temporal association to meno-
pause (approximately 60% appear to). The study suggests
that those starting HRT near to their menopause gained
the most benefit in terms of protection from hand OA.
In this protocol, to adhere to good practice in HRT pre-
scribing, we mandate that participants will be at least 1
year after final menstrual period, and that they have
established hand OA clinically. Whether this will prove
too late, either in terms of the course of their meno-
pause and/or their disease course to effect change on
symptoms is yet to be determined. That cessation of
HRT appears to be associated with onset of OA in this
study is further evidence for a modulatory role for these
agents, which needs to be better understood. It is im-
portant to note that here, the agent will be weaned grad-
ually over 4 weeks, rather than being stopped abruptly
to reduce the chances of any symptom flare.
To our knowledge, the study is unique, aiming to build
our knowledge of whether it is possible to intervene in a
poorly understood area, that of menopause and related
female musculoskeletal health issues. It seeks to assess a
potential tailored intervention for a group with high un-
met clinical need. It will also give us valuable informa-
tion on the best outcomes in this particular group of
women with the condition. Particular strengths of the
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study are its testing of feasibility and acceptability of dif-
ferent ways of collecting average hand pain, which is an
established outcome measure, although one that was
highlighted by participants in our PPI as inadequately
measured. HOPE-e is designed to determine whether a
large RCT treating symptomatic hand OA in post-
menopausal women with estrogen therapy is feasible.
The study opened to recruitment in May 2019 (IRAS ID
236463) and is anticipated to close in February 2021.
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